Blood-based RNA biomarker for the early detection of ovarian cancer
Tested in a cohort of 506 individuals, the RNA-based biomarker of microenvironment fitness Tu-stroma shows high performance in discriminating early-stage ovarian cancer from benign lesions, outperforming CA125.